Lotilaner + Vehicle Control
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Blepharitis
Conditions
Blepharitis
Trial Timeline
Oct 23, 2022 → Apr 2, 2024
NCT ID
NCT05629390About Lotilaner + Vehicle Control
Lotilaner + Vehicle Control is a phase 3 stage product being developed by LianBio for Blepharitis. The current trial status is completed. This product is registered under clinical trial identifier NCT05629390. Target conditions include Blepharitis.
What happened to similar drugs?
5 of 9 similar drugs in Blepharitis were approved
Approved (5) Terminated (1) Active (3)
🔄ISV-502 (1.0% azithromycin and 0.1% dexamethasone combined) + Azasite + DexamethasoneSun PharmaceuticalPhase 3
Hype Score Breakdown
Clinical
17
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05629390 | Phase 3 | Completed |
Competing Products
15 competing products in Blepharitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lotilaner ophthalmic solution, 0.25% + Vehicle control | Tarsus Pharmaceuticals | Approved | 37 |
| TP-03 + TP-03 Vehicle | Tarsus Pharmaceuticals | Phase 3 | 34 |
| TP-03, 0.25% + TP-03 Vehicle | Tarsus Pharmaceuticals | Phase 2/3 | 32 |
| ISV-305 | Sun Pharmaceutical | Phase 3 | 40 |
| ISV-502 (1.0% azithromycin and 0.1% dexamethasone combined) + Azasite + Dexamethasone | Sun Pharmaceutical | Phase 3 | 40 |
| AzaSite® | Merck | Approved | 43 |
| AzaSite® | Merck | Approved | 43 |
| AzaSite® | Merck | Approved | 43 |
| Azithromycin ophthalmic solution, 1% + Placebo | Merck | Phase 2 | 35 |
| AzaSite® | Merck | Approved | 43 |
| Azithromycin ophthalmic solution, 1% + Placebo | Merck | Phase 2 | 35 |
| Azithromycin ophthalmic solution, 1% + Vehicle | Merck | Phase 2 | 27 |
| Pimecrolimus 0.3% Ophthalmic Ointment + Placebo Ophthalmic Ointment | Viatris | Phase 3 | 29 |
| GLK-321 low dose BID + GLK-321 mid dose BID + GLK-321 high dose BID + GLK-321 high dose QD + Placebo BID | Glaukos | Phase 2 | 39 |
| KPI-121 + Vehicle | Kala Pharmaceuticals | Phase 2 | 25 |